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Abstract
Background: We examined lipid peroxidation (LPO) in blood mononuclear cells (BMCs) and plasma, as a marker of oxidative
damage, and its association to clinical symptoms in Fibromyalgia (FM) patients.
Methods: We conducted a case–control and correlational study comparing 65 patients and 45 healthy controls. Clinical
parameters were evaluated using the Fibromyalgia Impact Questionnaire (FIQ), visual analogues scales (VAS), and the Beck
Depression Inventory (BDI). Oxidative stress was determined by measuring LPO in BMCs and plasma.
Results: We found increased LPO levels in BMCs and plasma from FM patients as compared to normal control (P,0.001). A
significant correlation between LPO in BMCs and clinical parameters was observed (r = 0.584, P,0.001 for VAS; r = 0.823,
P,0.001 for FIQ total score; and r = 0.875, P,0.01 for depression in the BDI). We also found a positive correlation between
LPO in plasma and clinical symptoms (r = 0.452, P,0.001 for VAS; r = 0.578, P,0.001 for FIQ total score; and r = 0.579,
P,0.001 for depression in the BDI). Partial correlation analysis controlling for age and BMI, and sex, showed that both LPO in
cells and plasma were independently associated to clinical symptoms. However, LPO in cells, but not LPO in plasma, was
independently associated to clinical symptoms when controlling for depression (BDI scores).
Discussion: The results of this study suggest a role for oxidative stress in the pathophysiology of fibromyalgia and that LPO
in BMCs rather than LPO in plasma is better associated to clinical symptoms in FM.
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Introduction
Fibromyalgia (FM) is a common chronic pain syndrome with an
unknown etiology, which has been associated to a wide spectrum of
symptoms like allodynia, debilitating fatigue, joint stiffness and
depression. It is diagnosed according to the classification criteria
established by the American College of Rheumatology (ACR) [1].
Despite being a common disorder that affects at least 5 million
individuals in the United States [2], its pathogenic mechanism
remains elusive. Recently, oxidative stress has been proposed as a
relevant event in the pathogenesis of this disorder [3–6]. Previously,
our group has detected decreased coenzyme Q10 (CoQ10) levels and
increased mitochondrial reactive oxygen species (ROS) production
in blood mononuclear cells (BMCs) from FM patients [7,8]. In
addition, we have observed that CoQ10 and a-tocopherol, two
lipophilic antioxidants, induced a significant reduction of ROS in
BMCs from FM patients. Taken together, these results suggest that
ROS are produced in the lipophilic environment of mitochondrial
membranes and that CoQ10 deficiency may be involved in oxidative
stress in FM [7]. One of the consequences of ROS overproduction is
lipid peroxidation (LPO) leading to oxidative destruction of
polyunsaturated fatty acids constitutive of cellular membranes and
the production of toxic and reactive aldehyde metabolites such as
malondialdehyde (MDA) and 4-hydroxynonenal (HNE) [9,10].
These highly cytotoxic metabolites, produced in relatively large
amounts, can diffuse from their site of origin to attack distant targets
and form covalent bonds with various molecules [11–13].
Therefore, recognition of lipid peroxidation is of interest, as the
deleterious effects of this process might be prevented by adminis-
tration of scavenging systems or antioxidants. MDA assay is one of
the most popular methods for assaying LPO in plasma, serum or cell
lysates.
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Interestingly, there are discrepancies about the correlation
between symptoms and LPO and oxidative stress in FM.
Significant correlation has been observed between antioxidants
levels in plasma and serum, visual analogue scale (VAS) of pain,
and morning stiffness [3,6]. However, Bagis et al. found no
correlation between VAS of pain and LPO or superoxide
dismutase (SOD) in serum [4]. On the other hand, Ozgocmen
et al. found a significant correlation between depression and LPO
in serum but not between the biochemical parameters and clinical
measures of pain and fatigue [14]. We propose that this
controversy could be ascribed to a methodological problem
because LPO levels may show higher levels and reflect better
the degree of oxidative stress if LPO measurement is performed in
cells rather than in plasma or serum. This hypothesis is supported
by previous investigations suggesting that mitochondria were the
source of ROS in FM [15,16], and therefore, LPO levels in cells
can show better the severity of oxidative stress. Furthermore LPO
levels in plasma can be affected by the rate of detoxification by
others tissues. Consequently, important information may lack
when MDA is measured only in plasma or serum. Therefore we
examined the hypothesis that LPO levels in BMCs may be a better
oxidative marker than LPO levels in plasma to correlate more
significantly and independently with the clinical symptoms in FM
patients.
Methods
Ethics Statement
Informed consent written and the approval of the ethical
committee of University Pablo de Olavide and Universitary
Hospital Virgen Macarena from Seville were obtained.
Patients
In brief, 100 patients from the register of the Sevillian
Fibromyalgia Association (AFIBROSE) and 45 healthy matched
controls were enrolled into our study. Informed consent and the
approval of the local ethical committee were obtained. The
inclusion criterion during this study was: Patients diagnosed of FM
in the last 2–3 years, based on the current ACR diagnostic criteria
[1]. Exclusion criteria were acute infectious diseases in the
previous 3 weeks; past or present neurological, psychiatric,
metabolic, autoimmune, allergy-related, dermal or chronic
inflammatory disease; undesired habits (e.g., smoking, alcohol,
etc.); medical conditions that required glucocorticoid treatment,
use of analgesics, antidepressants drugs; past or current substance
abuse or dependence; and pregnancy or current breastfeeding.
Sixty-five potential participants met the inclusion criteria and were
enrolled into the study (males/5, females/60), and 35 patients
were excluded: 15 were smoker, 13 were using antidepressant
treatment, 5 had rheumatoid arthritis, and 2 had hepatitis c.
Forty-five healthy volunteers (males/5, females/40) were included
in the study matching the age range, gender, ethnicity, and
demographics (completion of at least 9 years of education and part
of the middle socioeconomic class) of the recruited female FM
subjects. Healthy controls had no signs or symptoms of FM and
were free of any medication for at least 3 weeks before the study
began. All patients and controls had not taken any drug or
vitamin/nutritional supplement during a 3 weeks period before the
collection of the blood samples. All patients and controls reported
followed a standard balanced diet (carbohydrate 50–60%, protein
10–20% and fat 20–30%) that was established by a diet program
during 3 weeks before blood collection. The diagnosis of FM was
established by an experienced rheumatologist according to ACR
criteria [1]. Clinical data were obtained from physical examina-
tion, and they were evaluated using the Fibromyalgia Impact
Questionnaire (FIQ) including visual analogues scales, and
depression with the Beck Depression Inventory (BDI). Tender
points were identified by digit pressure of the 18 locations
recommended by ACR which included a minimum of 11 out of
18. Heparinized and coagulated blood samples were collected
after 12-hours fasting from patients and controls, centrifuged at
3800 g for 5 min, and plasma and serum were stored at 280uC
until testing. Serum biochemical parameters were assayed by
routine analytical methods. Clinical data and blood samples were
collected in a time-frame of 2 months (September and October,
2009).
Isolation of BMCs
BMCs were purified from heparinized blood by isopycnic
centrifugation using Histopaque-1119 and Histopaque-1077
(Sigma Chemical Co., St. Louis, MO, USA).
Lipid peroxidation
Thiobarbituric acid reactive substances (TBARS) levels in
plasma and cells were determined by a method based on the
reaction with thiobarbituric acid (TBA) at 90–100uC using a
commercial kit from Cayman Chemical Company (Ann Arbor,
MI). TBARS are expressed in terms of malondialdehyde (MDA)
levels. In these assays, a MDA standard is used to construct a
standard curve against which unknown samples can be plotted.
Statistical analysis
All results are expressed as means 6SD unless stated otherwise.
The unpaired Student’s t test was used to evaluate the significance
of differences between groups. For correlation between LPO levels
in BMCs or plasma with clinical parameters, Pearsonn correlation
coefficient (r) was performed. Partial correlations for controlling
for confounders (BDI, age and BMI, and sex) were also performed.
The level of significance was set at p,0,05. As an indicator of
internal consistency reliability of the clinical questionnaires, we
calculated Cronbachs alpha values (achievable values range from
0, indicating no internal consistency, to 1, indicating identical
results). Cronbach’s alpha coefficient was 0.795 for FIQ and 0.812
for BDI. Cronbachs alpha values of more than 0.7 are commonly
considered markers of a high degree of reliability.
Results
Mean age in the FM group was 45.8611 years and in the
control group was 44.3612. Patient routine laboratory tests yield
normal results for glucose 90.05615.16 mg/dL (normal values,
n.v. 76–110) , urea 31.02611.35 mg/dL (n.v. 10–45), uric acid
4.0561.51 mg/dL (n.v.2.5–7.5), total protein 7.0260.90 g/dL
(n.v. 6.6–8.7), creatinine 0.8761.11 mg/dL (n.v. 0.5–1.1), aspar-
tate aminotransferase 23.5465.03 mU/mL (n.v. 10–40), alanine
aminotransferase 22.21610.33 mU/mL (n.v. 10–40), cholesterol
217636.17 mg/dL (n.v.,220), and triglycerides 99.13643.5 mg/
dL (n.v. 150–200).
We determined LPO, as a marker of oxidative stress-induced
membrane damage by mitochondrial ROS, in BMCs and plasma
from controls and FM patients. On average, FM patients showed
higher levels of LPO both in BMCs and plasma respect to controls
(p,0.001) (Figure 1A and 1B). Interestingly, LPO levels were
strikingly higher in cells (24.2 nmol/million cells = 48.4 nmol/ml
of cells lysate) than in plasma (14.17 nmol/ml of plasma) in FM
patients (p,0.001). Moreover, both parameters LPO levels in
BMCs and LPO levels in plasma were significantly associated.
(r = 0.618, P,0.001).
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Table 1 shows the clinical characteristics of patients and
controls. The mean duration of symptoms in the FM group was
10.466.4 years. The mean tender points in the FM group were
15.462.8 points (Table 1). The most prominent features of FM
patients were pain, fatigue, morning tiredness, and depression
(Table 1). As expected, FM patients had markedly higher levels of
pain (VAS, 5.961.8), depression (BDI, 18.568.5), and high
overall impact of FM (FIQ, 54.5616) than in normal controls
(P,0.001).
To study the association between LPO levels in BMCs or
plasma and clinical symptoms Pearsons correlation coefficient (r)
was performed. Table 2 shows a significant correlation between
LPO levels in BMCs and clinical parameters (r = 0.584, P,0.01
for VAS; r = 0.823, P,0.01 for FIQ total score; r = 0.564, P,0.01
for pain; r = 0.617, P,0.01 for fatigue; r = 0.574, P,0. 01 for
morning tiredness; r = 0.669, P,0.01 for stiffness; r = 0.591,
P,0.01 for anxiety; r = 0.632, P,0.01 for depression in the
FIQ; r = 0.875, P,0.01 for depression in the BDI).
LPO levels in plasma were also significantly associated to
clinical parameters (r = 0.452, P,0.01 for VAS; r = 0.578, P,0.01
for FIQ total score; r = 0.410, P,0.01 for pain; r = 0.311, P,0.05
for fatigue; r = 0.397, P,0.01 for morning tiredness; r = 0.402,
P,0.01 for stiffness; r = 0.433, P,0.01 for anxiety; r = 0.561,
P,0. 01 for depression in the FIQ; r = 0.579, P,0.01 for
depression in the BDI).
Interestingly, correlations were higher for both LPO levels in
BMCs and plasma with depression than with other clinical
parameters.
Next, partial correlation analysis was used to determine the
strength of the association of LPO levels in cells or plasma with
clinical symptoms, after controlling for depression (BDI), age and
BMI, and sex, respectively (Table 3). Partial correlation analysis
showed that LPO levels in cells were independently correlated
with clinical symptoms, indicating that this significant association
was not mediated by depression, age and BMI or sex (Table 3).
However, it is remarkable that this association was reduced when
Figure 1. Lipid peroxidation (MDA levels) in BMCs (Panel A) and plasma (Panel B) from controls and FM patients was determined as
described in Material and Methods. Data represent the mean6SD of three separate experiments. *P,0,001 between control and FM patients.
doi:10.1371/journal.pone.0026915.g001
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controlling for depression (Table 2 and 3). LPO levels in plasma
were also independently associated to clinical parameter when
controlling for age and BMI and sex. However, the association of
LPO levels in plasma and clinical symptoms was eliminated when
depression was controlled.
Discussion
The essential findings of this study are that FM patients have
significantly elevated levels of LPO in BMCs and plasma (MDA
measured as TBARS). Moreover our results show that LPO levels
in BMCs are more strongly and independently associated than
LPO levels in plasma with FM symptoms. The results presented
suggest the involvement of oxidative stress as part of the
pathophysiology of FM.
A large number of studies have shown high levels of oxidative
stress markers, such as LPO levels, in FM patients, suggesting that
this process may have a role in the pathophysiology of this disease.
Additionally, we have also shown that BMCs can be an excellent
model to study the relation between oxidative stress and FM.
[8,15].
Our results show that FM patients present increased LPO levels
in both BMCs and plasma compared to healthy controls, a finding
in line with studies by other groups investigating oxidative stress
markers in FM [4,15]. Furthermore, the patients show high levels
of pain, fatigue, stiffness, depression, and a high overall impact of
FM.
But, what is the relationship between LPO and FM symptoms?
It is known that LPO, as a consequence of oxidative stress,
indirectly reflects intracellular ROS generation, and ROS are
known to be implicated in the etiology of pain, one of the most
prominent symptoms in FM, by inducing peripheral and central
hyperalgesia [17]. Superoxide plays a major role in the
development of pain through direct peripheral sensitization, the
release of various cytokines (for example, TNF-a, IL-1b, and IL-6),
the formation of peroxynitrite (ONOO-), and poly (ADP-ribose)
polymerase activation (PARP) [17]. Although, the mechanisms by
which increased oxidative stress can affect specifically muscle
sensitivity remain to be established, it may be that oxidative
damage in muscles results in threshold lowering of nociceptors
locally, thus producing and altered nociception [18].
Furthermore, increased LPO has been described in patients
suffering from depression and fatigue, two typical symptoms found
in FM patients [19,20]. Studies on depression have elucidated a
possible link between depression and LPO [21], and the
peroxidation-reducing effect of different selective serotonin
reuptake inhibitors in major depression has been demonstrated
by Bilici et al. [19]. It has been suggested that alterations in
phospholipids which are structural components of cell membrane
in the brain, may induce changes in membrane microviscosity
and, consequently, in various neurotransmitter systems, which are
thought be related to the pathology of depression, e.g., serotonin
(5-HT), and noradrenaline [22,23]. LPO of cell membranes can
modify receptor accessibility, dynamics, ligand binding and action,
and therefore altering neurotransmitter functions [24]. Oxidative
stress may also affect the expression of membrane functional
proteins and receptors, by interfering with intracellular signalling
and receptors turnover, including serotonergic receptors [25].
The fact that depression was associated to both LPO in BMCs
and plasma can be ascribed to the fact that neuron membranes
can be more vulnerable to oxidative stress due to its high content
in polyunsaturated fatty acids [23], and consequently neurotrans-
mitters pathways involved in depression may be more easily
affected.
Furthermore, this association was higher with LPO in BMCs
than in plasma in all the clinical parameters analyzed. These
findings could be ascribed to the presence of higher levels of LPO
in BMCs than in plasma that can reflect better the severity of
oxidative stress, and thus, showing a better association to clinical
symptoms in FM. MDA is a end-product of LPO, and its cellular
accumulation indicates oxidative damage in the cells. However,
plasma MDA levels depend on the balance between MDA
formation and its detoxification and can be affected for many
factors, such as the dilutional effect of plasma, and the renal and/
or tissue clearance. The fact that severity of FM symptoms
apparently correspond better with BMCs MDA values than
plasma MDA values, might be also speculated as a predominant
contribution of the inflammatory cells in the severity of FM
symptoms.
Furthermore, depression per se is accompanied by an induction
of inflammatory and oxidative and nitrosative stress pathways,
Table 1. Characteristic findings of the FM patients and
control group.
Patients Control
Age (years) 45.8 611 44.3 612
Tender points 15.4 62.8 ?
Duration of disease (years) 10.4 66.4 ?
Sex (male/female) 5/60 5/40
BMI (Kg/m2) 27.4 6 4.2 23.3 6 0.9
VAS Total score 5.9 61.8* 0.5 6 0.8
FIQ Total score, range 0 80 54.5 616.* 3 61.6
Pain 7.3 62.2* 0.7 60.3
Fatigue 7.6 6 1.9* 1.2 6 0.9
Morning tiredness 6.7 62.2* 1.1 61.0
Stiffness 5.9 62.3* 0.6 60.1
Anxiety 5.8 62.7* 1 60.9
Depression 5.2 62.7* 1.2 60.8
Beck Depression Inventory 18.5 68.6* 4 6 1.9
Values are means 6SD.
*P,0.001.
doi:10.1371/journal.pone.0026915.t001
Table 2. Correlation between lipid peroxidation (LP) and
clinical findings in FM patients.
Patients
r
Control
r
VAS Total score 0.584** 0.452**
FIQ Total score 0.823** 0578**
Pain 0.564** 0.410**
Fatigue 0.617** 0.311*
Morning tiredness 0.574** 0.397**
Stiffness 0.669** 0.402**
Anxiety 0.591** 0.433**
Depression 0.632** 0.561**
Beck Depression Inventory 0.875** 0.579**
*P,0.05.
**P,0.01; r, Pearson’s Correlation Coefficient.
doi:10.1371/journal.pone.0026915.t002
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altered cytokine activity [26], increased LPO levels and a lowered
antioxidant status [27–29]. All these alterations, which may
reinforce themselves through a feedback mechanism (depression
induces LPO and LPO induces depression), make a significant a
much stronger case for the association between LPO levels in cells
or plasma and depression in FM patients.
The inflammation, oxidative and nitrosative stress theory of
depression offers an explanation why depression may be caused by
psychological stressors and the presence of (auto)immune disorders
[28]. The latter is indeed accompanied by inflammatory responses
that may induce oxidative and nitrosative stress whereby NO and
peroxynitrite are formed by for example activated neutrophils and
monocytes, which in turn may cause oxidation and nitration of
fatty acids, proteins and DNA. Psychological stressors may
generate oxidative stress and even cause damage to fatty acids
and DNA. Firstly, emotional stressors induce inflammatory
reactions with an increased production of pro-inflammatory
cytokines [30], which cause ROS and reactive nitrogen species
(RNS). Secondly, psychological stressors induce a pro-oxidant state
and LPO [31,32]. Therefore, the high comorbidity between FM
and depression may be explained because both share overlapping
pathophysiological processes [33,34].
Furthermore, we examined the independence of LPO levels and
clinical parameters association in FM and the modulating role of
depression (BDI) and others confounders (age and BMI, and sex).
Partial correlation analysis showed that LPO levels in BMCs
correlated with clinical symptoms independently of depression, age
and BMI, and sex in FM patients. Interestingly, this association
was reduced when controlling for depression, suggesting that in
some extend depression is modulating LPO levels in BMCs. On
the contrary, LPO levels in plasma were not associated with
clinical parameters when controlling for depression, suggesting
that depression has a confounding effect on LPO levels in plasma
in FM patients.
In conclusion, our study confirms the presence of LPO in BMCs
and plasma in FM patients. LPO levels in BMCs are better
associated than LPO levels in plasma to clinical symptoms in FM.
Furthermore, this association, although significantly independent,
is modulated by depression. Finally, the results of this study
indicate that oxidative stress could be implicated in the severity of
the clinical symptoms in FM and suggest that antioxidant therapy
needs to be examined as a treatment in FM. Recently, The role of
oxidative stress in peripheral neuropathic pain was recently tested
by assessing the effects of antioxidants (acetyl-L-carnitine, alpha-
lipoic acid, and vitamin C) on pain behavior in a rat model of
neuropathic pain [32]. Our results might also be relevant for the
clinical management of FM patients since the effectiveness of
treatment could be additionally tested by serial BMCs LPO
determinations during the course of the treatment.
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